Your Messages Inbox
Your Article Summary
See Latest ArticlesConsidering Usual Medical Care in Clinical Trial Design
PLoS Medicine, 09/30/09
Dawson L et al. – The goal should be that each trial will contribute to the accumulation of knowledge via a sequence of investigations, which together lead to a causally coherent understanding of treatment effects. So an investigator must be able to look beyond the trial in question and explain how its results will inform future research that lead to such an understanding. Studies implementing “usual care” arms can complicate this task, but if done right can ultimately lead to results of great scientific relevance and practical value.
Related Articles
Increase in Quality, but Not Quantity, of Clinical Trials in Acute Pain: 1992 Versus 2007
Anesthesia & Analgesia, 10/21/09
Relevance Score: 69%
Cytokinetics Announces Advancement of CK-2017357 in Phase I Clinical Trials
Cytokinetics, 11/10/09
Relevance Score: 68%
Methodological aspects of lung cancer clinical trials in the era of targeted agents
Lung Cancer, 11/03/09
Relevance Score: 68%
Boston Scientific Announces Exclusive Sponsorship and First Enrollments of MADIT-RIT Clinical Trial
Boston Scientific, 10/06/09
Relevance Score: 68%
Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data
Cancer Chemotherapy and Pharmacology, 10/05/09
Relevance Score: 68%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
MediGene AG Decides on a Revision of the Development Plans for EndoTAG(TM)-1 and RhuDex(TM), and Downsizes its Executive Board
MediGene, 12/15/09
Second Pivotal Phase III Study of Gileads Darusentan for Resistant Hypertension Misses Primary Endpoints
Gilead, 12/15/09
Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis
Genentech, 12/15/09
Article Search
Sponsor